- Home
- GNRC vs PCVX Comparison
GNRC vs PCVX Comparison
Compare GNRC & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNRC
- PCVX
- Stock Information
- Founded
- GNRC 1959
- PCVX 2013
- Country
- GNRC United States
- PCVX United States
- Employees
- GNRC N/A
- PCVX N/A
- Industry
- GNRC Metal Fabrications
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- GNRC Consumer Discretionary
- PCVX Health Care
- Exchange
- GNRC Nasdaq
- PCVX Nasdaq
- Market Cap
- GNRC 9.7B
- PCVX 12.5B
- IPO Year
- GNRC 2010
- PCVX 2020
- Fundamental
- Price
- GNRC $142.11
- PCVX $116.70
- Analyst Decision
- GNRC Buy
- PCVX Strong Buy
- Analyst Count
- GNRC 20
- PCVX 7
- Target Price
- GNRC $156.94
- PCVX $139.17
- AVG Volume (30 Days)
- GNRC 613.7K
- PCVX 1.2M
- Earning Date
- GNRC 07-31-2024
- PCVX 11-04-2024
- Dividend Yield
- GNRC N/A
- PCVX N/A
- EPS Growth
- GNRC 62.49
- PCVX N/A
- EPS
- GNRC 3.90
- PCVX N/A
- Revenue
- GNRC $4,021,807,000.00
- PCVX N/A
- Revenue This Year
- GNRC $7.94
- PCVX N/A
- Revenue Next Year
- GNRC $8.91
- PCVX N/A
- P/E Ratio
- GNRC $36.42
- PCVX N/A
- Revenue Growth
- GNRC N/A
- PCVX N/A
- 52 Week Low
- GNRC $79.86
- PCVX $44.20
- 52 Week High
- GNRC $169.57
- PCVX $119.27
- Technical
- Relative Strength Index (RSI)
- GNRC 42.02
- PCVX 85.77
- Support Level
- GNRC $138.89
- PCVX $77.21
- Resistance Level
- GNRC $157.64
- PCVX $119.27
- Average True Range (ATR)
- GNRC 4.32
- PCVX 3.81
- MACD
- GNRC -1.48
- PCVX 3.96
- Stochastic Oscillator
- GNRC 20.20
- PCVX 94.02
About GNRC Generac Holdlings Inc.
Generac designs and manufactures power generation equipment serving residential, commercial, and industrial markets. It offers standby generators, portable generators, lighting, outdoor power equipment, and a suite of clean energy products. Sales generated in the United States account for the majority of total sales.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.